Drilldown: Medicines

Other values:

Search

None (78) · (none, never marketed) (1) · Dalmane (1) · Delysid (historical, Sandoz, withdrawn 1965) (1) · Doral (1) · Doriden (1) · Halcion (1) · Hetlioz (1) · Imovane (1) · Lunesta (1) · Mogadon (1) · Nembutal (1) · Placidyl (1) · ProSom (1) · Quaalude (1) · Restoril (1) · Rohypnol (1) · Rozerem (1) · Seconal (1) · Sonata (1) · Strattera (1) · THIP (1) · Versed (1) · Xyrem (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

5-HT2A agonist (26) · GABAA positive allosteric modulator (15) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · None (3) · GABAA positive allosteric modulator (non-benzodiazepine) (3) · Contains LSA (2) · Contains mescaline (2) · GABAA potentiator and direct activator (2) · Melatonin receptor agonist (2)

Other values:

Search

None (99) · No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) · '"`UNIQ--vote-00000013-QINU`"' (1)

None (99) · Children ≤70 kg: 0.5 mg/kg/day, titrate to 1.2 mg/kg/day after 3 days. Adults and children >70 kg: 40 mg PO once daily for 3 days, then 80 mg/day, then if needed 100 mg/day after 2-4 weeks (1) · No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1)

None (99) · Capsules 10, 18, 25, 40, 60, 80, 100 mg (1) · Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1)

None (99) · 100 mg/day (adult); 1.4 mg/kg/day or 100 mg total (pediatric, whichever lower) (1) · N/A (never approved) (1)

None (98) · intranasal; rectal and IV reported. (1) · Oral (3) · sublingual (1)

None (98) · 30–60 minutes (1) · ADHD effect emerges over 1-2 weeks (slower than psychostimulants); full effect 4-6 weeks (1) · ~20–40 min PO; faster sublingual/intranasal. (1)

None (98) · 24 hours (once-daily or split BID dosing) (1) · 6–10 h subjective; full pharmacologic effect considerably longer. (1) · 8–12 hours (1)

None (98) · 3–5 hours (1) · Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1) · ~5 hours in extensive CYP2D6 metabolizers; ~21 hours in CYP2D6 poor metabolizers'"`UNIQ--ref-00000014-QINU`"' (1)

None (98) · 70–90% (oral) (1) · Not formally characterized in humans. (1) · ~63% (oral; extensive first-pass)'"`UNIQ--ref-00000015-QINU`"' (1)

None (98) · Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) · Limited human data.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Not established (1)

None (99) · Schedule I (United States) (1) · [[USLegal:Prescription only|Rx-only]] in US. '''Not a controlled substance''', the principal clinical selling point versus psychostimulant ADHD options. Carries the antidepressant-class '''Boxed Warning''' for suicidal ideation in pediatric patients'"`UNIQ--ref-00000016-QINU`"' (1)